This technology employs a chicken-derived polyclonal IgY antibody raised against an 8 kDa recombinant NRG1 peptide, designed to detect multiple NRG1 isoforms in a sensitive sandwich ELISA assay. It specifically targets a unique peptide sequence to avoid common epitope competition issues, enabling the reliable detection of full-length NRG1, rNRG1.2, and rNRG1.1/NeucardinTM. With a detection threshold of approximately 100 pg/mL—nearly three orders of magnitude more sensitive than typical assays—it offers precise measurement of low endogenous levels in clinical samples, which is especially crucial in monitoring cardiovascular biomarkers.
Description
This approach is differentiated by its novel use of IgY antibodies from chickens, which provides superior selectivity and minimizes cross-reactivity compared to conventional antibodies. Unlike existing ELISAs that rely on antibodies facing competition for the same target domain, this system circumvents such limitations and offers enhanced sensitivity and scalability for clinical deployment. Its ability to accurately quantify very low levels of NRG1 positions it as a critical tool for advancing cardiovascular research and optimizing therapeutic interventions in clinical trial settings.
Applications
- Cardiovascular diagnostic assay
- Heart failure biomarker detection
- Clinical trial patient monitoring
- Therapeutic dosing assessment
Advantages
- Enables highly sensitive detection of NRG1 levels (down to ~100 pg/mL), significantly outperforming conventional neuregulin ELISAs.
- Specifically recognizes multiple NRG1 isoforms—including full-length, rNRG1.1/NeucardinTM, and rNRG1.2—ensuring comprehensive profiling.
- Avoids epitope competition in the sandwich ELISA format by targeting a unique sequence, enhancing assay accuracy.
- Offers a clinically deployable and scalable diagnostic tool to monitor both endogenous and therapeutically administered NRG1 levels.
IP Status
Research Tool
